Definium Therapeutics, Inc. (DFTX)
Definium Therapeutics develops treatments based on psychedelic compounds for brain health disorders such as anxiety, depression and autism. It last closed at $29.38 on Nov 17, down 2.59% on the day. DFTX last reported earnings on Mon, Nov 9, 2026. The average 12-month price target from 5 analysts is $75.60 (+157.3% from the last close), with a high of $85.00 and a low of $66.00. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 4 whale options trades in DFTX, 50% of them bullish and 50% bearish.
Key Stats
Last 12 monthsNot reported for this period.
From DFTX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 5 analysts who set a price target on DFTX in the past 90 days. The average target is $75.60, with a high of $85.00 and a low of $66.00, compared with the last close of $29.38.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 17 | JP Morgan | Maintained | Buy | $85 |
| Nov 10 | RBC Capital | Target raised | Buy | $66 → $70 |
| Oct 9 | JP Morgan | Initiated | Buy | $84 |
| Sep 15 | Canaccord Genuity | Target raised | Buy | $64 → $78 |
| Sep 15 | Baird | Target raised | Buy | $75 → $79 |
Technical Analysis
The stock is 16% below its 20 day and 22% below its 50 day average. It is 4% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the Pivot S1 at $28.38, and the nearest resistance the Pivot at $29.45.
| RSI (14) | 35.77 | Weak, oversold below 30 | Neutral |
| MACD | -1.34 | Below its signal line | Bearish |
| Stochastic | 10.4 | Near the bottom of its range | Oversold |
| ADX (14) | 17.5 | No clear trend | |
| Williams %R | -91.3 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -166.1 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −12.1% | Change over 10 sessions | Bearish |
| ATR (14) | $2.07 | Typical daily range, 7.1% of price |
| RSI (14) | 42.25 | Middle of its range | Neutral |
| MACD | 0.82 | Below its signal line | Bearish |
| Stochastic | 10.6 | Near the bottom of its range | Oversold |
| ADX (14) | 40.1 | Strong downtrend | |
| Williams %R | -95.1 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -147.0 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −24.4% | Change over 10 sessions | Bearish |
| ATR (14) | $4.70 | Typical daily range, 16.0% of price |
What happened before
See how DFTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How DFTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.
Whale Options Flow
90DNo whale options trades in DFTX in the last 90 days.
DFTX Institutional Ownership
Full report →- ▲199 buying vs 167 selling
- ▲Held by funds +2.2 pts
- ▼Funds holding -9
- ▼Superinvestors: 0 added, 4 cut
- ▲Put/call 0.22 to 0.19
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 354 | 363 | −2.5% |
| In funds' top 10 | 10 | 13 | −23.1% |
| Held by funds | 86.1% | 84.0% | +2.2 pts |
| New / increased | 62 / 137 | 144 / 116 | −23.5% |
| Reduced / sold out | 97 / 70 | 64 / 30 | +77.7% |
| Put/call ratio | 0.19 | 0.22 | −12.0% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DFTX is in one of them and how their past DFTX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered DFTX in an article yet. Here's the latest on the wider market.
About Definium Therapeutics
Definium Therapeutics is a drug developer based in New York that is working on treatments for brain health conditions. Its main product candidates are derived from psychedelic and empathogen compounds. The lead candidate, DT120, is being tested in adults with generalized anxiety disorder and major depressive disorder, and a second candidate, DT402, is being studied in adults with autism spectrum disorder. None of its products are approved for sale yet, and the company is aiming to offer them to patients under medical care.
- Headquarters
- New York, NY
- Website
- definiumtx.com ↗


